Article

The Antiviral Mechanism of Action of Molnupiravir in Humans with COVID-19

2023-11-27

Abstract excerpt

Meaningful metrics of antiviral activity are essential for determining the efficacy of therapeutics in human clinical trials. Molnupiravir (MOV) is a broadly acting antiviral nucleoside analog prodrug that acts as a competitive alternative substrate for the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp). We developed an assay, Culture-PCR, to better understand the impact of MOV therapy on infectious SARS-CoV-2. Cu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4f7a9f81-e36f-5030-9bbd-bc0249a83223
DOI: 10.1101/2023.11.21.23298766

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The Antiviral Mechanism of Action of Molnupiravir in Humans with COVID-19DOI 10.1101/2023.11.21.23298766Read

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral ActivitySemantic proximity Read

Molnupiravir, an Oral Antiviral Treatment for COVID-19Semantic proximity Read

Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA VirusesSemantic proximity Read

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in miceSemantic proximity Read

Virological and Clinical Outcomes in Adults Treated with Ribavirin Aerosol for COVID-19 PneumoniaSemantic proximity Read

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 VariantsSemantic proximity Read

Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 TreatmentSemantic proximity Read

Antiviral treatments lead to the rapid accrual of hundreds of SARS-CoV-2 mutations in immunocompromised patientsSemantic proximity Read

Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2.Semantic proximity Read

Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2Semantic proximity Read

OM-85 reduces SARS-COV-2 viral RNA expression in nasopharyngeal cells from COVID-19 patientsSemantic proximity Read

A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2Semantic proximity Read